Forward-Looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation statements related to the commercial launch of DIFICID in
Canada, Optimer's ability to quickly provide DIFICID to physicians and patients in
Canada, and expected trends in the incidence of CDI. Words such as "believes", "would", "anticipates", "plans", "expects", "may", "intend", "will", and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. These forward-looking statements are based on management's expectations on the date of this release. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: Optimer's ability to commercialize DIFICID in
Canada, the ability of Optimer and its third party contractors to manufacture and supply sufficient quantities of DIFICID in accordance with Good Manufacturing Practices to meet demand, the ability of Optimer to adequately prepare for the launch of DIFICID in
Canada, including its ability to hire, maintain and manage a sales force in
Canada, the development of alternative treatments for or means of preventing CDI, whether healthcare professionals will prescribe DIFICID, whether DIFICID will receive reimbursement coverage and other risks detailed in Optimer's filings with the Securities and Exchange Commission
ContactsOptimer Pharmaceuticals, Inc. David Walsey, Vice President, Investor Relations and Corporate Communications858-964-3418
Canale Communications, Inc.
Jason I. Spark, Senior Vice President619-849-6005
OPTIMER and DIFICID are trademarks of Optimer Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.
SOURCE Optimer Pharmaceuticals, Inc.